A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults

Drug and Alcohol Dependence

Volumn 177, Issue , 2017, Pages 249-257

  Gray, Kevin M ^a   Sonne, Susan C ^a   McClure, Erin A ^a   Ghitza, Udi E ^b   Matthews, Abigail G ^c   McRae Clark, Aimee L ^a   Carroll, Kathleen M ^d   Potter, Jennifer S ^e   Wiest, Katharina ^f   Mooney, Larissa J ^g   Hasson, Albert ^g   Walsh, Sharon L ^h   Lofwall, Michelle R ^h   Babalonis, Shanna ^h   Lindblad, Robert W ^c   Sparenborg, Steven ^b   Wahle, Aimee ^c   King, Jacqueline S ^c   Baker, Nathaniel L ^a   Tomko, Rachel L ^a   Haynes, Louise F ^a   Vandrey, Ryan G ⁱ   Levin, Frances R ^j   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c EMMES CORPORATION   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^f CODA Inc ^*  (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

more..

Author keywords

Addiction; Cannabis; Cessation; Marijuana; N acetylcysteine; Pharmacotherapy; Treatment

Indexed keywords

ACETYLCYSTEINE; CANNABINOID; PLACEBO; CANNABIS; SCAVENGER; SULPIRIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT REFUSAL; URINALYSIS; URINE LEVEL; ADOLESCENT; CANNABIS SMOKING; CLINICAL TRIAL; MULTICENTER STUDY; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ACETYLCYSTEINE; ADOLESCENT; ADULT; CANNABIS; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MEDICATION ADHERENCE; SULPIRIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020754004     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.04.020     Document Type: Article

References (34)

1. American Psychiatric Association, 2000, Diagnostic and statistical manual of mental disorders, fourth ed., text rev. Author, Washington, DC.
2. Avants, S.K., Margolin, A., Holford, T.R., Kosten, T.R., A randomized controlled trial of auricular acupuncture for cocaine dependence. Arc. Intern. Med. 160 (2000), 2305–2312.
3. Baker, D.A., McFarland, K., Lake, R.W., Shen, H., Tang, X.C., Toda, S., Kalivas, P.W., Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat. Neurosci. 6 (2003), 743–749.
4. Bickel, W.K., Stitzer, M.L., Bigelow, G.E., Liebson, I.A., Jasinski, D.R., Johnson, R.E., A clinical trial of buprenorphine:Comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 43 (1988), 72–78.
5. Budney, A.J., Moore, B.A., Development and consequences of cannabis dependence. J. Clin. Pharmacol. 42:Suppl. 11 (2002), 28–33.
6. Budney, A.J., Moore, B.A., Rocha, H.L., Higgins, S.T., Clinical trial of abstinence-based vouchers and cognitive-behavioral therapies for cannabis dependence. J. Consult. Clin. Psychol. 74 (2006), 307–316.
7. Cooper, K., Chatters, R., Kaltenthaler, E., Wong, R., Psychological and psychosocial interventions for cannabis cessation in adults:A systematic review short report. Health Technol. Assess. 19 (2015), 1–130.
8. Copeland, J., Pokorski, I., Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst. Abuse Rehabil. 7 (2016), 41–53.
9. First, M., Spitzer, R., Gibbon, M., Williams, J., Structured Clinical Interview for Axis I Disorders. patient edition, 2004, Biometrics Research New York State Psychiatric Institute, New York.
10. Gates, P.J., Sabioni, P., Copeland, J., Le Foll, B., Gowing, L., Psychosocial interventions for cannabis use disorder. Cochrane Database Syst. Rev., 5, 2016, CD005336.
11. Gray, K.M., Carpenter, M.J., Baker, N.L., DeSantis, S.M., Kryway, E., Hartwell, K.J., McRae-Clark, A.L., Brady, K.T., A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am. J. Psychiatry 169 (2012), 805–812.
12. Haney, M., Bedi, G., Cooper, Z.D., Glass, A., Vosburg, S.K., Comer, S.D., Foltin, R.W., Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol. Psychiatry 73 (2013), 242–248.
13. Hasin, D.S., Saha, T.D., Kerridge, B.T., Goldstein, R.B., Chou, S.P., Zhang, H., Jung, J., Pickering, R.P., Ruan, W.J., Smith, S.M., Huang, B., Grant, B.F., Prevalence of marijuana use disorders in the United States between 2001 and 2002 and 2012–2013. JAMA Psychiatry 72 (2015), 1235–1242.
14. Hasin, D.S., Kerridge, B.T., Saha, T.D., Huang, B., Pickering, R., Smith, S.M., Jung, J., Zhang, H., Grant, B.F., Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiological survey on alcohol and related conditions-III. Am. J. Psychiatry 173 (2016), 588–599.
15. Heishman, S.J., Evans, R.J., Singleton, E.G., Levin, K.H., Copersino, M.L., Gorelick, D.A., Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 102 (2009), 35–40.
16. Herron, A.J., Mariani, J.J., Pavlicova, M., Parrinello, C.M., Bold, K.W., Levin, F.R., Nunes, E.V., Sullivan, M.A., Raby, W.N., Bisaga, A., Assessment of riboflavin as a tracer substance:Comparison of a qualitative to a quantitative method of riboflavin measurement. Drug Alcohol Depend. 128 (2013), 77–82.
17. Johnson, B.A., Rosenthal, N., Capece, J.A., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O'Malley, S.S., Swift, R.M., Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group, Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298 (2007), 1641–1651.
18. Liang, K.Y., Zeger, S.L., Longitudinal data analysis using generalized linear models. Biometrika 73 (1986), 13–22.
19. Malcolm, R., Kajdasz, D.K., Herron, J., Anton, R.F., Brady, K.T., A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 60 (2000), 161–168.
20. Mariani, J.J., Brooks, D., Haney, M., Levin, F.R., Quantification and comparison of marijuana smoking practicesBlunts, joints, and pipes. Drug Alcohol Depend. 113 (2011), 249–251.
21. Marshall, K., Gowing, L., Ali, R., Le Foll, B., Pharmacotherapies for cannabis dependence. Cochrane Database Syst. Rev., 12, 2014, CD008940.
22. McClure, E.A., Gipson, C.D., Malcolm, R.J., Kalivas, P.W., Gray, K.M., Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 28 (2014), 95–106.
23. McClure, E.A., Sonne, S.C., Winhusen, T., Carroll, K.M., Ghitza, U.E., McRae-Clark, A.L., Matthews, A.G., Sharma, G., Van Veldhuisen, P., Vandrey, R.G., Levin, F.R., Weiss, R.D., Lindblad, R., Allen, C., Mooney, L.J., Haynes, L., Brigham, G.S., Sparenborg, S., Hasson, A.L., Gray, K.M., Achieving cannabis cessation −evaluating N-acetylcysteine treatment ACCENT): design and implementation of a multi-site, randomized controlled study in the national institute on drug abuse clinical trials network. Contemp. Clin. Trials 39 (2014), 211–223.
24. Molton, J.S., Pang, Y., Wang, Z., Qiu, B., Wu, P., Rahman-Shepherd, A., Ooi, W.T., Paton, N.I., Prospective single-arm interventional pilot study to assess a smartphone-based system for measuring and supporting adherence to medication. BMJ, 6, 2016, e014194.
25. Montgomery, L., Petry, N.M., Carroll, K.M., Moderating effects of race in clinical trial participation and outcomes among marijuana-dependent young adults. Drug Alcohol Depend. 126 (2012), 333–339.
26. Montgomery, L., Carroll, K.M., Petry, N.M., Initial abstinence status and contingency management treatment outcomes: does race matter?. J. Consult. Clin. Psychol. 83 (2015), 473–481.
27. Peters, E.N., Schwartz, R.P., Wang, S., O'Grady, K.E., Blanco, C., Psychiatric, psychosocial, and physical health correlates of co-occurring cannabis use disorders and nicotine dependence. Drug Alcohol Depend. 134 (2014), 228–234.
28. Peterson, C.M., Apolzan, J.W., Wright, C., Martin, C.K., Video chat technology to remotely quantify dietary, supplement and medication adherence in clinical trials. Br. J. Nutr. 116 (2016), 1646–1655.
29. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The mini-international neuropsychiatric interview M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:Suppl. 20 (1998), 22–33.
30. Sobell, L.C., Sobell, M.B., Leo, G.I., Cancilla, A., Reliability of a timeline method:Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br. J. Addict. 83 (1988), 393–402.
31. Trivedi, M.H., Greer, T.L., Rethorst, C.D., Carmody, T., Grannemann, B.D., Walker, R., Warden, D., Shores-Wilson, K., Stoutenberg, M., Oden, N., Silverstein, M., Hodgkins, C., Love, L., Seamans, C., Stotts, A., Causey, T., Szucs-Reed, R.P., Rinaldi, P., Myrick, H., Straus, M., Liu, D., Lindblad, R., Church, T., Blair, S.N., Nunes, E.V., Randomized controlled trial comparing exercise to health education for stimulant use disorder: results from the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J. Clin. Psychiatry, 2017, 10.4088/JCP.15m10591.
32. Volkow, N.D., Baler, R.D., Compton, W.M., Weiss, S.R.B., Adverse health effects of marijuana use. N. Engl. J. Med. 370 (2014), 2219–2227.
33. Volpicelli, J.R., Pettinati, H.M., McLellan, A.T., O'Brien, C.P., Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. 2001, Guilford, New York.
34. Winhusen, T.M., Kropp, F., Lindblad, R., Douaihy, A., Haynes, L., Hodgkins, C., Chartier, K., Kampman, K.M., Sharma, G., Lewis, D.F., VanVelhuisen, P., Theobald, J., May, J., Brigham, G.S., Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J. Clin. Psychiatry 75 (2014), 757–764.